Transgenomic declared that Craig Tuttle, the company’s President and Chief Executive Officer, had given a detailed presentation on the latest findings of its ultra-sensitive DNA mutation detection technology called COLD-PCR.
The presentation was held at BIT Life Sciences' 2nd World DNA and Genome Day Conference from 25 to 30 April, 2011 in Dalian, China. A total of nine Nobel Laureates participated in the meeting.
US Congress announced that April 25 will be celebrated as National DNA Day. The April month was celebrated as Genome Month to mark the anniversary of Francis Crick and James Watson publication of DNA Double Helix Structure. The title of the presentation was "Ultra-sensitive DNA Mutation Detection: COLD-PCR Applied to Key Cancer Pathway Gene Mutations in Circulating Plasma DNA".
According to Transgenomic's CEO, Craig Tuttle the latest results revealed that the COLD-PCR can be used to locate mutations in free circulating tumor DNA in serum or plasma even with the existence of non-tumor derived DNA. He further confirmed that this technique will allow periodical, non-invasive viewing of serum or plasma samples. The samples obtained can be used to detect cancer and track resistance to therapy or post-treatment relapse and remission.
Source: http://www.transgenomic.com/